It was reported that the procedure was to treat a heavily calcified, mildly tortuous, 90% stenosed lesion in the left anterior descending (lad) artery.The lesion was pre-dilatated with a 3x12mm traveler balloon dilatation catheter (bdc) and a 2.5x48mm xience xpedition drug eluting stent (des) was implanted at the target lesion.Post-dilatation was completed with a 2.5x12mm nc traveler bdc, after which a distal end dissection was noted.A 2.5x12mm xience xpedition was implanted to cover the dissection and successfully complete the procedure.There was no adverse patient sequela.No additional information was provided.
|
The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effect of dissection is listed in the xience xpedition 48, everolimus eluting coronary stent system (eecss), instructions for use (ifu) as a known patient effect of coronary stenting procedures.A conclusive cause for the reported patient effect, and the relationship to the product, if any, cannot be determined; however, the subsequent treatment appears to be related to the operational context of the procedure.Based on the information reviewed, there is no indication of a product quality issue with respect to manufacture, design or labeling.The xience xpedition 48 is currently not commercially available in the us; however, it is similar to a device sold in the us.
|